BioMerieux SA
BIM
Company Profile
Business description
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
Contact
Marcy l’Etoile
Lyon69280
FRAT: +33 478872000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
15,226
Stocks News & Analysis
stocks
Big four bank holds up in weakening economic conditions
Major bank earnings hold up in challenging conditions.
stocks
Our view after Coles’ shares plunge
Shares dropped 8% after reporting results for the September 2026 quarter.
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,977.20 | 48.20 | -0.53% |
| CAC 40 | 8,047.69 | 78.27 | 0.98% |
| DAX 40 | 25,981.09 | 162.88 | 0.63% |
| Dow JONES (US) | 51,983.98 | 213.67 | 0.41% |
| FTSE 100 | 10,761.33 | 31.55 | 0.29% |
| HKSE | 23,393.32 | 98.90 | 0.42% |
| NASDAQ | 25,164.31 | 272.68 | -1.07% |
| Nikkei 225 | 63,081.86 | 208.25 | -0.33% |
| NZX 50 Index | 13,647.87 | 50.76 | -0.37% |
| S&P 500 | 7,541.40 | 38.67 | -0.51% |
| S&P/ASX 200 | 8,856.50 | 51.60 | -0.58% |
| SSE Composite Index | 3,638.03 | 39.01 | 1.08% |